Justifying high-cost anticoagulant therapy

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL. 6, 2002, Pages

  Racine, Eric ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulants; Costs; Dosage; Drugs; Heparins; Hospitals; Pharmacoeconomics; Toxicity

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; DANAPAROID; ENOXAPARIN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BUDGET; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HOSPITAL COST; HOSPITALIZATION; HUMAN; OSTEOPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0037108959     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_6.s18     Document Type: Conference Paper

References (4)

1. American College of Clinical Pharmacy. Vision statement. ACCP Rep. 1997; 16:S1-8.
2. Sanchez LA. Pharmacoeconomics: principles, methods, and applications to pharmacotherapy. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford, CT: Appleton & Lange; 1999:1-11.
3. Vichiendilokkul A. Breaking out of the silo: one health system's experience. Am J Health-Syst Pharm. 2002; 59 (suppl 6):S15-7.
4. Mark DB, Cowper PA, Berkowitz SD et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation. 1998; 97:1702-7.